Enrolling by invitationEarly Phase 1NCT07358234

Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

Studying NON RARE IN EUROPE: Eosinophilic esophagitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mayo Clinic
Principal Investigator
Diana Snyder, M.D.
Mayo Clinic
Intervention
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT](drug)
Enrollment
60 enrolled
Eligibility
18 years · All sexes
Timeline
20262027

Collaborators

Vanderbilt University Medical Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07358234 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Eosinophilic esophagitis

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Eosinophilic esophagitis

← Back to all trials